> You'd think there'd be some similar studies done of the original result but that doesn't seem to have been the case or this fraud would've been discovered alr

> You'd think there'd be some similar studies done of the original result but that doesn't seem to have been the case or this fraud would've been discovered already. As Derek Lowe says, this did happen: > I could be wrong about this, but from this vantage point the original Lesné paper and its numerous follow-ups have largely just given people in the field something to point at when asked about the evidence for amyloid oligomers directly affecting memory. I’m not sure how many groups tried to replicate the findings, although (as just mentioned) when people did it looks like they indeed couldn’t find the 56 oligomer. And judging from the number of faked Westerns, that’s probably because it doesn’t exist in the first place. But my impression is that a lot of labs that were interested in the general idea of beta-amyloid oligomers just took the earlier papers as validation for that interest, and kept on doing their own research into the area without really jumping directly onto the 56 story itself. The bewildering nature of the amyloid-oligomer situation in live cells has given everyone plenty of opportunities for that! The expressions in the literature about the failure to find *56 (as in the Selkoe lab’s papers) did not de-validate the general idea for anyone - indeed, Selkoe’s lab has been working on amyloid oligomers the whole time and continues to do so. Just not Lesné’s oligomer. In other words, the result was tried to be replicated a few times, and no one could replicate it. But the groups working in this space were already pursuing similar paths before this paper, and the results were taken not as a "target this one specific thing and you'll be golden" but rather "here's more evidence that targeting this class of thing is useful in this place." I'll also point out that by the time you're talking dosage questions, you're generally tackling clinical trials (phase II trials are meant to establish the dosing regime), which is far downstream of work that gets published academically.